SME



Diamante SRL

www.diamante.tech

Diamante SRL, is a spin-out company from the University of Verona, Italy that exploits plants as bioreactors for the production of modified plant virus nanoparticles, used in developing new tools for autoimmune disease diagnosis.

DIAMANTE exploits plants as bioreactors for the sustainable production of nanoparticles based on modified plant viruses that are used in developing new tools in autoimmune disease diagnosis. Plant viruses are exploited as a scaffold in order to stabilize and display high numbers of functional peptides. Through a fast and environmental-friendly production process DIAMANTE provides innovative nanomaterials employable employable for several applications.
Our Our first product is an innovative kit for Sjogren’s Syndrome (SjS) diagnosis which able enables to identify patients to be identified with a higher specificity and a sensitivity higher that theto current SjS diagnostic tools. Moreover, our kit is patient-friendly because as it needs only requires a blood sample for diagnosis.

Our nanoparticles display up to 1300 peptide copies and allows to improves the diagnostic performance. Using plants, we can reach high yields of nanomaterials without the need of expensive bioreactors and culture media.


Key people


Linda Avesani, Workpackage 7 Lead

Linda is an assistant professor in the Department of Biotechnology (University of Verona) and CSO in Diamante srl. Linda’s research activities have always been focused on the use of molecular farming to find new solutions for autoimmune diseases therapy and diagnosis. PhD in plant biotechnology, CEO of Officina Biotecnologica srl is author of more than 20 publications and two patents related to plant genetics and biotechnology.




Valentina Garonzi, CEO of Diamante srl.

Valentina graduated in Business Administration and Corporate Law and is currently studying for a Masters in Management at Mip MIP - Politecnico di Milano with a focus on Risk Enterprise Management. Valentina ran different collaborations with other start-ups in the developing a business strategiesy to enter the market.

Mark
                 
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 774078.


Pharma Factory copyright 2018